Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of oral dersimelagon in erythropoietic protoporphyria and X-linked protoporphyria
2021-001831-17Phase 3Active
- Sponsor
- Mitsubishi Tanabe Pharma Development America
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), sponsored by Mitsubishi Tanabe Pharma Development America. Primary endpoint: Treatment-emergent adverse events. Started Nov 2021; status: active.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on 2021-001831-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001831-17.